论文部分内容阅读
自Jordan(1961)首次报告口服避孕药发生血栓症以来,有许多病例和病组报告提供了一些有启发性的证据,即口服避孕药可诱致凝血亢进而使血栓栓塞症的发生率增加。另有不少资料提示妊娠晚期或产褥后给予雌激素制剂时常可见凝血亢进状态,甚至有人报告血栓症发生异常地增加。至今虽个别报告否认,但绝大多数学者均承认在此状态下可出现凝血亢进。研究证明其中起作用的是雌激素成份,并与其在体内量的多少密切相关。但雌激素致凝血亢进血栓形成的机理很复杂,尚未完全阐明。其中与凝血抑制因子-抗凝血酶Ⅲ(AT-Ⅲ)之间的关系,正成为近年研究重视的问题。即雌激素有抑制AT-Ⅲ
Since the first report by Jordan (1961) of thrombosis of oral contraceptives, there are many case and group reports that provide some encouraging evidence that oral contraceptives can induce hypercoagulability and increase the incidence of thromboembolism. There are many other data suggest that during pregnancy or post-puerperal estrogen preparations often visible hyperthyroidism, and some even reported an abnormal increase in thrombosis. Although a few reports have denied so far, the vast majority of scholars admit that there may be hyperthyroidism in this state. Studies have shown that the role of which is estrogen ingredients, and its amount in the body is closely related. However, the mechanism of estrogen-induced thrombosis is complex and not yet fully elucidated. Among them, the relationship with coagulation inhibitor-antithrombin Ⅲ (AT-Ⅲ) is becoming a research focus in recent years. That is, estrogen has AT-Ⅲ inhibition